Evaluation of Microbiota and Weight Alterations After the Administration of Tetracycline and Lactobacillus gasseri in Rats

Olimpio, Fernando S.; Fiol, Fernando de Sá Del; Lima, Renata de; Rosa, Karina S.; Roque, Guilherme Augusto Sanches; Santos, Cintia V.; Piletz, John E.

doi:10.1007/s00284-020-02090-4

Cited by 4 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…clinical side-effects associated with long-term tetracycline usage (e.g., gut dysbiosis and tooth calcification) and the growing concerns related to antibiotic resistance, any such novel riboswitch should be designed to respond to an activating ligand that is not an antibiotic and has greater bioavailability than tetracycline, which has been shown to inefficiently cross the blood brain barrier 75,76 . Several alternative riboswitches exist, including those with greater dynamic range, including GuaM8HDV and TAP1, which are responsive to guanidine HCL and theophylline, respectively, but it is unknown whether these ligands are readily absorbed through the blood aqueous barrier 45,46,[77][78][79][80] .…”

Section: Discussionmentioning

confidence: 99%

Prostaglandin-based rAAV-mediated glaucoma gene therapy in Brown Norway rats

et al. 2022

View full text Add to dashboard Cite

Prostaglandin analogs are first-line treatments for open angle glaucoma and while effective at lowering intraocular pressure, they are undermined by patient non-compliance, causing atrophy of the optic nerve and severe visual impairment. Herein, we evaluate the safety and efficacy of a recombinant adeno-associated viral vector-mediated gene therapy aimed at permanently lowering intraocular pressure through de novo biosynthesis of prostaglandin F2α within the anterior chamber. This study demonstrated a dose dependent reduction in intraocular pressure in normotensive Brown Norway rats maintained over 12-months. Crucially, therapy could be temporarily halted through off-type riboswitch activation, reverting intraocular pressure to normal. Longitudinal multimodal imaging, electrophysiology, and post-mortem histology revealed the therapy was well tolerated at low and medium doses, with no major adverse effects to anterior chamber health, offering a promising alternative to current treatment strategies leading to clinically relevant reductions in intraocular pressure without the need for adherence to a daily treatment regimen.

show abstract